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Abstract
Glucagon is a 29-amino acid peptide hormone secreted by pancreatic α-cells and
interacts with specific receptors located in various organs. Glucagon tends to form
gel-like fibril aggregates that are cytotoxic because they activate apoptotic signaling
pathways. First, fibril formation by glucagon in acidic solution is discussed in light
of morphological and structural changes during elapsed time. Second, we provide
kinetic analyses using a two-step autocatalytic reaction mechanism; the first step is
a homogeneous nuclear formation process, and the second step is an autocatalytic
heterogeneous fibril elongation process. Third, the processes of fibril formation by
glucagon in a membrane environment are discussed based on the structural changes
in the fibrils. In the presence of bicelles in acidic solution, glucagon interacts with
the bicelles and forms fibril intermediates on the bicelle surface and grows into
elongated fibrils. Glucagon-dimyristoylphosphatidylcholine (DMPC) bilayers in
neutral solution mimic the environment for fibril formation by glucagon under
near-physiological condition. Under these conditions, glucagon forms fibril inter-
mediates that grow into elongated fibrils inside the lipid bilayer. Many days after
preparing the glucagon-DMPC bilayer sample, the fibrils form networks inside and
outside the bilayer. Furthermore, fibril intermediates strongly interact with lipid
bilayers to form small particles.
Keywords: glucagon fibril, fibrillation mechanism, two-step autocatalytic reaction,
lipid bilayer, solid-state NMR
1. Introduction
Glucagon is a 29-amino acid peptide hormone secreted by pancreatic α-cells and
interacts with specific receptors located in various organs, where it activates the
glycogenolysis and gluconeogenic pathways, resulting in raised blood glucose levels
[1–3]. Glucagon tends to form gel-like fibrillar aggregates in acidic condition [4].
These aggregates are cytotoxic due to the activation of apoptotic signaling pathways
[5]. These fibrils are similar to those of other therapeutic peptides and proteins such
as human calcitonin (hCT) [6] and insulin [7] and pathologically related fibrils such
as prion [8], amylin (type 2 diabetes) [9], β-amyloid (Alzheimer’s disease) [10], and
polyglutamine [11].
Some non-fibrillar proteins and peptides have been observed by electron
microscopy to form amyloid fibrils with similar morphologies [12].
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Several characteristics of these fibrils are related to the misfolding of proteins,
leading to severe conditions such as fibril deposits in the brains of Alzheimer’s
disease patients [13] and in the pancreas of patients with type 2 diabetes [9].
Kinetic analyses of fibril formation by the therapeutic peptide human calcitonin
indicate that hCT molecules associate to form fibril intermediates via a two-step
autocatalytic reaction mechanism. The first step of kinetic reaction (rate constant,
k1) is a homogeneous reaction from micelle-like oligomers to fibril intermediates.
These intermediates react with monomeric molecules to elongate into longer fibrils
via a heterogeneous fibril elongation process (rate constant, k2) [14–17]. Elucidating
the molecular structure of amyloid fibrils is important for understanding the mech-
anism of self-aggregation, but it is difficult to determine high-resolution molecular
structures using typical spectroscopic methods because fibrils are heterogeneous
solids. Solid-state NMR spectroscopy has demonstrated advantages for the confor-
mational determination of Alzheimer’s amyloid β-peptides (Aβ), which mainly
comprise 40 or 42 amino acid residues and are the main component of the amyloid
plaques found in Alzheimer’s disease patients [12, 18]. Both the intra-chain confor-
mation of the Aβ molecule in fibrils and their intermolecular alignment have been
analyzed to explore the mechanism of molecular association underlying the forma-
tion of Aβ (1–40) [19–21] and the more toxic Aβ (1–42) [22–24] fibrils.
The primary structure of the glucagon peptide is His1-Ser-Gln-Gly-Thr5-Phe-
Thr-Ser-Asp-Tyr10-Ser-Lys-Tyr-Leu-Asp15-Ser-Arg-Arg-Ala-Gln20-Asp-Phe-Val-
Gln-Trp25-Leu-Met-Asn-Thr-OH.
An X-ray crystallographic study showed that glucagon adopts a trimeric α-helix
structure stabilized by hydrophobic interactions between molecules related by
threefold symmetry [25], whereas a solution NMR study showed that glucagon in
dilute aqueous solution may not form a specific structure, with the exception of the
22–25 region [26]. The secondary structure of glucagon in the presence of
dodecylphosphocholine micelles comprises three turns of an irregular α-helix
formed by residues 17 to 29 near the C-terminus, a stretch of extended polypeptide
chain from residues 14 to 17, an α-helix-like turn formed by residue 10 to 14, and
another extended region from residue 5 to 10 [27].
Fibril formation by glucagon molecules was observed by Beaven et al. in
undisturbed aqueous solution at pH 2 [4]. The viscosity initially increased and a
birefringent gel is formed. With time, a precipitate appeared comprising long
fibrils, as determined using electron microscopy. Infrared spectra of the gel, solid
film, and precipitate showed that in all these states, glucagon is in the form of
antiparallel β-sheet chains [5, 28]. Kinetic analysis of fibril formation by glucagon
under acidic conditions demonstrated a complex fibrillation mechanism in
which suitable changes in the fibrillation condition can alter the type of fibril
formed or result in the formation of a mixture of several types of fibrils [29, 30].
Furthermore, the fibrils come in two forms: one composed entirely of glucagon
monomers and the other entirely of glucagon trimers [31]. Studies of fibril forma-
tion typically use acidic pH solutions because of the low solubility of glucagon in
neutral solution.
Understanding the cytotoxicity of amyloid-forming peptides requires investi-
gating the interaction of these peptides with membranes because lipid bilayer com-
ponents dramatically alter most aspects of amyloid aggregation [32–35]. We
previously reported glucagon fibrillation in the presence of dimyristoylphosphati-
dylcholine/1,2-dihexanoyl-sn-glycero-3-phophocholine (DMPC-DHPC) bicelles in
acidic solution. The glucagon structure in the fibril in the presence of these bicelles
is different from that in their absence [36]: the N- and C-termini both change from
α-helix to β-sheet in acidic solution, while the N-terminus remains in an α-helical
conformation, whereas the C-terminus changes from α-helix to β-sheet in the
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presence of bicelles. The nucleation rate is slower, and the fibril elongation rate is
faster in acidic solution than in the presence of bicelles.
In neutral conditions, glucagon molecules are incorporated into lipid bilayers
above the phase transition temperature, and the properties of the lipids appear to
remain unperturbed. Below the phase transition temperature, glucagon forms dis-
coidal particle with DMPC [37, 38] and induces closer packing of the phospholipid
bilayers [39]. Similar peptide-lipid interaction to form discoidal particles below the
phase transition temperature is seen in the melittin-DMPC bilayer system [40, 41].
The time course behavior of glucagon fibril formation inside a DMPC bilayer
under neutral conditions, which approximates the physiological condition, and the
kinetic behavior of glucagon under these conditions have been investigated to
understand the fibrillation process under near-physiological conditions [42].
2. Fibril formation by glucagon in acidic solution
Gel formation by glucagon in the β-sheet conformation in acid solutions is a
relatively slow process at room temperature [4] and can be followed by observing
the change in viscosity as shown in Figure 1. The most marked feature of the
change in viscosity in these time profiles is the presence of a substantial lag phase
during which oligomeric nuclei are likely formed and function as initiation sites.
These phenomena were confirmed by adding a small seed of preformed glucagon
gel on the end of a wire into a viscometer containing a fresh acidic glucagon
solution. The viscosity increased immediately with essentially no lag (Figure 1a).
After a prolonged reaction time, the viscosity began to decrease and fibrils some-
times precipitated. These fibrils represent a variant of the β-structure of glucagon.
Fibril formation strongly depends on the peptide concentration, proceeding very
slowly at less than about 1.5 mg/ml and occurring more readily at higher concen-
tration (Figure 1b). Increasing the ionic strength of the solution results in both an
increasing aggregation rate and more rapid production of fibrils. The change in
viscosity with time in even 0.01 M sodium chloride occurs much more rapidly than
in the absence of salt, and viscosity decreases quickly.
The effect of temperature on the polymerization rate is also very marked. Both
the aggregation rate and the size of the aggregates as reflected in the maximal values
of the reduced viscosity show a strong temperature maximum around 30°C
(Figure 1c). An addition of 5% (v/v) of the nonaqueous solvent dioxin completely
inhibits the aggregation (Figure 1a).
Transmission electron microscopy (TEM) time-elapsed pictures were obtained
during fibril formation by glucagon dissolved in 0.015 M acetic acid solution
(18 mg/ml) at pH 3.3 [36]. TEM pictures were measured approximately 2 hrs, then
1 week, and 6 months after the dissolution of glucagon (Figure 2). A small number
of spherical-shaped fibril intermediates appeared after approximately 2 hrs, as
shown in Figure 2a. After 1 week, the number of spherical fibril intermediates had
increased, and elongated fibrils had appeared (Figure 2b). After 6 months, long
mature fibrils about 10 nm in diameter were observed, and the spherical fibril
intermediates had completely disappeared (Figure 2c).
The α-helical content of aged glucagon at 5.0 mg/ml decreased significantly to
approximately 1%. The CD spectrum of a β-sheet structure typically shows an
intense positive band at 198 nm and a negative band at 218 nm [5]. The CD spectral
pattern of aged glucagon was that of a β-sheet structure, indicating a conforma-
tional transition from α-helical to β-sheet structure under these conditions.
The FTIR spectrum of glucagon immediately after dissolution showed a low-
intensity β-sheet band at 1620–1630 cm1, and aging resulted in progressively
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greater amounts of β-sheet [28]. Deconvolution and curve fitting of the amide I
band showed that unaged glucagon contained 54% α-helix/random coil structure
and 2% β-sheet structure, whereas aged glucagon comprised 22% α-helix/random
coil structure and 49% β-sheet structure.
Detailed kinetic, spectroscopic, and morphological studies have revealed that
glucagon can form several types of fibrils that differ at the level of molecular
packing of the peptide [29–31, 43–46]. Each type forms through distinct
Figure 1.
Time course behavior of glucagon aggregation in 0.01 M hydrochloric acid at 26°C and a glucagon
concentration of 2.5 mg/ml. (a) Time course of reduced viscosity (msp/c); glucagon with no addition (○);
glucagon seeded with preformed gel (□); glucagon solution containing 5% by volume dioxin (●). (b) Effect of
glucagon concentration at 4 mg/ml (□); 2.5 mg/ml (○); and 1 mg/ml (●). (c) Effect of temperature on the
aggregation rate of glucagon at a glucagon concentration of 2.5 mg/ml at 26°C (○); 30°C (□); and 35°C (∇)
(ref. [4]).
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nucleation-dependent aggregation pathways influenced by the solution conditions
and can be self-propagated by seeding. Type A fibrils that form at high glucagon
concentration (>5 mg/ml, pH 2.5) represent the least stable fibril type with a low
melting midpoint (Tmapp < 32°C) and single protofilament fibrils observable by
TEM (Figure 3a). Type B (Bunagitated and Bagitated) fibrils form under low glucagon
concentration (<0.5 mg/ml, pH 2.5). Type Bunagitated fibrils grow by branching in
the absence of agitation and appear as branched twisted fibrils by TEM (Figure 3b).
Type Bagitated glucagon fibrils form when the solution is agitated, suggesting that
agitation breaks the fibril creating more free fibril ends that align as parallel pairs
(Figure 3c). Type D fibrils grow under low glucagon concentration (<0.5 mg/ml,
pH 2.5) in the presence of 150–250 mM Cl and are twisted and tightly packed
Figure 2.
Transmission electron micrographs of glucagon (18 mg/ml) in 0.015 M acetic acid solution at pH 3.3.
(a) Taken approximately 2 hrs after the dissolution of glucagon. The bar indicates 20 nm. (b) Taken
1 week after dissolution of glucagon. The bar indicates 50 nm. (c) Taken 6 months after dissolution of glucagon.
The bar indicates 50 nm (ref. [36]).
Figure 3.
Electron microscope image of morphology of different types of glucagon fibrils. The scale bar is 50 nm. (a)
Type A: The glucagon concentration, >5 mg/ml, 50 mM glycine, pH 2.5, low agitation. (b) Type Bunagitated:
Glucagon concentration, <0.5 mg/ml, 50 mM glycine, pH 2.5, low agitation. (c) Type Bagitated: Glucagon
concentration, <0.5 mg/ml, 50 mM glycine, vigorous agitation. (d) Type D: Glucagon concentration,
<0.5 mg/ml, 50 mM glycine, pH 2.5+, 150–250 mM Cl. (e) Type S: Glucagon concentration, <0.5 mg/ml,
0.01 N HCl, 1 mM SO4
2 (ref. [30]).
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(Figure 3d). Type S fibrils grow under low glucagon concentration (<0.5 mg/ml,
pH 2.5) in the presence of 1 mM Na2SO4 (7:1 ratio with glucagon) and appear as
twisted mature fibrils by TEM (Figure 3e).
Solid-state 13C NMR spectra were observed for 18 mg/ml [1-13C]Gly4 and
[3-13C]Ala19-glucagon in 0.015 M acetic acid solution, pH 3.3 [36]. The 13C direct
excitation with dipolar decoupling and magic angle spinning (DD-MAS) signal
indicates monomeric glucagon, and the 13C cross polarization with magic angle
spinning (CP-MAS) signal indicates fibril glucagon. The DD-MAS spectra
(Figure 4A and C) of [1-13C]Gly4 and [3-13C]Ala19 exhibit signals at 171.7 and
16.4 ppm, respectively, consistent with the monomeric state and indicate that the
region near the Gly4 and Ala19 residues forms α-helix structures, as shown by the
conformationally dependent chemical shift values [47, 48, 49]. The experimentally
determined chemical shift values and secondary structures are summarized in
Table 1. The 13C CP-MAS spectra of [1-13C]Gly4 and [3-13C]Ala19 (Figure 4B andD)
Figure 4.
13C DD-MAS and CP-MAS NMR spectra of [1-13C]Gly4 (A and B) and [3-13C]Ala19 (C and D) of
[1-13C]Gly4 and [3-13C]Ala19-glucagon in acetic acid solution at pH 3.3. Schematic structures of glucagon in
the monomeric and fibril states (right panels) (ref. [36]).
Fibril formation condition Fibril type [1-13C]Gly4
(structure)
[3-13C]Ala19
(structure)
Ref.
Acidic solution (0.015 M acetic acid
solution pH 3.3)
Monomer 171.7 (α-helix) 16.4 (α-helix) [36]
Fibril 169.2 (β-sheet) 21.0 (β-sheet) [36]
Acidic solution in the presence of bicelle
(DMPC+DHPC pH 3.3)
Monomer 171.5 (α-helix) 16.4 (α-sheet) [36]
Fibril 171.5 (α-helix) 19.3 (β-sheet) [36]
Glucagon inside lipid bilayer (DMPC) in
neutral solution
Monomer 171.5 (α-helix) 15.9 (α-helix) [42]
Intermediate 168.9 (β-sheet) 20.5 (β-sheet) [42]
Fibril 166.9 (β-sheet) 21.5 (β-sheet) [42]
*The structure around each amino acid residues was determined by comparing the experimentally obtained 13C
chemical shift values (δiso) with typical
13C chemical shift values (δiso) of α-helix and β-sheet, reported as 171.6 and
168.5 for [1-13C]Gly and 14.9 and 19.9 for [3-13C]Ala, respectively [47, 48, 49].
Table 1.
Structural transitions during glucagon fibrillation in various conditions as determined by conformation-
dependent 13C chemical shifts (ppm)*.
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of glucagon in the fibril state exhibit signals at 167.2 and 21.0 ppm, respectively, and
indicate that the vicinities of Gly4 and Ala19 form β-sheet structures.
Conformationally dependent chemical shift values [47–49] clearly indicate that
the N-terminus of monomeric glucagon forms an α-helix structure, the center
portion forms a random coil, and the C-terminus forms an α-helix structure, as
shown in Table 1 and Figure 4 (right panels) in acetic acid solution. When the
glucagon monomer aggregates to form fibrils, the N-terminal and C-terminal
regions change from an α-helix to a β-sheet as seen with other amyloid-forming
peptides such as human calcitonin [14] in acetic acid solution.
3. Cytotoxicity of glucagon fibril
The cytotoxicity of the glucagon fibril was assessed by exposing PC12 and
NIH-3 T3 cells to 0.1–100 μM peptide aggregate for 72 hrs followed by cell viability
determination under the WST-8 assay and released lactate dehydrogenase (LDH)
[5]. A significant decrease in cell viability was observed in cultures exposed to
10–100 μM aged glucagon (P < 0.01) but not in cultures treated with 100 μM
nonaged glucagon. It was determined whether the loss of cell viability was due to
cell death by measuring the release of LDH. Treatment with 10 μM aged glucagon
induced a significant increase in LDH release compared to control, whereas no
significant increase in LDH release was observed in cultures treated with 100 μM
nonaged glucagon or 1 μM or lower aged glucagon. Thus, glucagon fibrils were
found to be highly toxic to PC12 cells, similar to the case of aged prion protein
fragment (PrP)106–126 [50] and β-amyloid (Aβ)1–42 [51] (>10 mM). Aged salmon
calcitonin also displayed significant cytotoxicity in PC12 cells, whereas nonaged
salmon calcitonin did not induce significant cell death [5].
Next, signaling pathways for the cytotoxicity of peptide fibrils were investigated
[5]. Caspase-3 activation is required for the early stages of apoptosis that include
DNA fragmentation and morphological changes. To determine whether aged glu-
cagon induces caspase-3 activation in PC12 cells, cells were exposed to 50 μM aged
glucagon, and the caspase-3-like activities of the cell lysates were measured by
cleavage of the fluorometric caspase-3 substitute Z-DEVD-rhodamine 110.
The activity increased prior to the loss of membrane integrity, and 24 hrs after
incubation, maximum caspase-3 activity was detected (160% of the control level).
In contrast, no significant elevation of casepase-3 activity was observed in cells
treated with 50 μM nonaged glucagon. These results indicate that the exposure of
PC12 cells to peptide fibrils induces a rapid (within 24 hrs) and significant elevation
in casepase-3 activity prior to the loss of cell viability 72 hrs after exposure.
In summary, the misfolding of the therapeutic peptide glucagon generates
amyloidogenic fibrils, leading to cytotoxicity mediated by the activation of the
apoptotic enzyme caspase-3 in vitro.
4. Kinetic analysis of the glucagon fibrillation process
As shown in Figure 5, glucagon monomers (A) first aggregate to form weakly
coupled oligomers (An) akin to the micelle state. Next, glucagon oligomers (An)
form fibril intermediates (nuclei) (Bn) through a homogeneous nucleation process
with a rate constant k1. Fibril intermediates (Bn) then react with monomer (A) to
form elongated fibrils with a rate constant k2. This is called the inhomogeneous
fibril elongation process. The B form plays a role in the catalysis of A to B, and
therefore this is an autocatalytic reaction. Since the nucleation and elongation
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processes are rate-determining steps, fibril formation is a two-step autocatalytic
reaction.
The rate constants of glucagon fibril formation were determined by observing
the signal intensities of [1-13C]Gly4 in [1-13C]Gly4 and [3-13C]Ala19-glucagons by
13C CP-MAS NMR spectroscopy with time (Figure 6A and B). The signal intensities
increased after a delay time. The increase in 13C CP-MAS signal intensities corre-
sponds to the increase in fibril components, and thus we obtained the rate con-
stants, k1 and k2, for the two-step autocatalytic reaction mechanism, in which k1 is
the rate constant for the fibril nucleation process and k2 is the rate constant for the
fibril elongation process [14].
The first reaction step is homogeneous nuclear formation given by
Ano !
k1
Bno, (1)
where Ano is the micelles formed by no number of A-form glucagon monomers
and Bno is the fibrils formed by no number of B-form glucagon fibrils. The kinetic
equation for Reaction (1) can be given by
df=dtð Þ1 ¼ k1 1 fð Þ, (2)
Figure 5.
Schematic of the glucagon fibril formation process in acidic solution. Several monomers (A) aggregate to form
weakly coupled micelles (An). Micelles (An) form a fibril nucleus (Bn) through a homogeneous nucleation
process with a rate constant k1. Fibril nuclei react with monomers (A) to form elongated fibrils (Bn + 1) with a
rate constant k2. In this reaction, B acts as a catalyst to change the A form to the B form. Overall, this fibril
formation reaction is a two-step autocatalytic reaction mechanism.
Figure 6.
(A) Time course of changes in the 13C CP-MAS and DD-MAS signals of [1-13C]Gly-glucagon during the fibril
formation processes [36]. (B) Plot of normalized CP-MAS signal intensity against elapsed time for glucagon
fibril formation in acidic solution at pH 3.3 [36]. (C) Plot of normalized turbidity intensities against elapsed
time for glucagon fibril formation in neutral solution (20% acetonitrile solution, pH 7.5) [42].
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where f is the fraction of B-glucagon fibrils in the system.
The second heterogeneous fibril elongation reaction can be given by k2
Aþ Bn !
k2
Bnþ1, (3)
where Bn and Bn + 1 are elongated fibrils with n and n + 1 number of B-form
glucagons. The relevant kinetic equation is given by
df=dtð Þ2 ¼ k2af 1 fð Þ, (4)
where a is the initial concentration of glucagon. The overall kinetic equation can
be given by
df=dtð Þ ¼ df=dtð Þ1 þ df=dtð Þ2 ¼ k1 1 fð Þ þ k2a 1 fð Þ, (5)
Eq. (5) can be integrated to give
f ¼
ρ exp 1þ ρð Þkt½   1f g
1þ ρ exp 1þ ρð Þkt½ f g
(6)
where f is the fraction of glucagon molecules in the fibril form at time t and ρ
represents a dimensionless value describing the ratio of k1 (the rate constant for
the first nucleation process) to k, namely, ρ = k1/k and k = ak2 (k2 is the rate
constant for the second elongation process of the fibrils, and a is the initial peptide
concentration) [14]. The best fits of Eq. (6) are shown in Figure 6B (solid lines),
and the analyzed rate constants are summarized in Table 2. The k1 and k2 values
were obtained experimentally from the intensity variation of the 13C CP-MAS NMR
signals of [1-13C]Gly4 as shown in Figure 6B and Table 2 for glucagon in acidic
solution. In comparison, rate constants of fibril formation were obtained for gluca-
gon in neutral solution by plotting the turbidity of the solution against the elapsed
time by using an established protocol [52] (Figure 6C).
The intensity of the 13C CP-MAS NMR signal of [1-13C]Gly4 was plotted against
the elapsed time for glucagon in the presence of bicelles in acidic solution and for
glucagon embedded inside lipid bilayers in neutral solution. The obtained rate
constants are given in Table 2.
5. Fibril formation by glucagon in the presence of bicelles in acidic
solution
In the presence of bicelles (DMPC-DHPC; 3:1), the N-terminus of glucagon
forms an α-helix, the center portion forms a random coil, and the C-terminus forms
Fibril formation condition k1 (s
1) k2 (s
1 M1) Ref.
Acidic solution (0.015 M acetic acid pH 3.3) 2.6  108 1.8  102 [36]
Neutral solution
(20% acetonitrile pH 7.5)
1.2  1024 4.4  10 [42]
Acidic solution (pH 3.3) in the presence of bicelle (DMPC+DHPC) 2.3  106 2.8  103 [36]
Inside a lipid bilayer (DMPC) in neutral solution (pH 7.5) 2.8  107 5.7  104 [42]
Table 2.
Rate constants for glucagon fibril nucleation (k1) and fibril elongation (k2) for a two-step autocatalytic
reaction mechanism under a variety of conditions.
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an α-helix in the monomeric state (Table 1). In contrast to glucagon in acetic acid
solution, the aggregation of monomers into the fibrils in the presence of bicelles
results in the N-terminus maintaining an α-helix structure and the center portion
remaining in a random coil structure, whereas the C-terminus changes from an α-
helix to a β-sheet structure (Figure 7 and Table 1). There is therefore significant
difference in the structural transition between monomer and fibril in the presence
and absence of bicelles, since the N-terminus maintains an α-helix structure in the
process of fibril formation in the presence of bicelles. This result suggests that the
N-terminal portion of a glucagon fibril significantly interacts with the lipid bilayer
surface.
The above findings provide insights into the mechanism of fibril formation in
the presence and absence of lipid bilayers, as shown in Figure 7. In the absence of
lipid bilayers, monomers may aggregate with each other to form oligomeric inter-
mediates (similar to micelles) through a homogeneous reaction (Figure 7B; left),
likely driven by the amphipathic natures of the N-terminal and C-terminal α-heli-
ces. These oligomeric intermediates then change into spherical fibril intermediates
(Figure 7C; left) as observed by TEM (Figure 2a and b). Subsequently, these
spherical fibril intermediates may form fibril nuclei and interact with monomeric
glucagon to allow elongation of the fibril by changing from an α-helix to a β-sheet
through a heterogeneous elongation process (Figure 7D; left).
In the presence of lipid bilayers, monomers form a structure similar to that in
the absence of lipid bilayers. The monomers likely associate quickly with the lipid
bilayer and subsequently associate with other monomers to form weakly coupled
oligomeric intermediates (Figure 7B; right). These oligomeric intermediates may
change their structure to form fibril intermediates on the surface of the lipid bilayer
and are observed as ellipsoid-shaped fibril intermediates (Figure 7C; right and TEM
picture) on the surface of the lipid bilayer. The elliptical shape is due to the N-
terminal region retaining an α-helix structure even in the fibril intermediates.
Figure 7.
Schematic diagram of the fibrillation processes of glucagon in acetic acid solution (left) and acidic solution in
the presence of bicelles (center). (A) Monomeric form. (B) Weakly coupled oligomer. (C) Fibril intermediate.
(D) Elongated fibril. TEM pictures of glucagon fibril intermediates with ellipsoidal shapes and of disk-type
bicelles are seen in the top right photo. An elongated fibril is seen attached by its end to a bicelle in the bottom
right photo (ref. [36]).
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The fibril intermediates grow into longer fibrils on the surface of the lipid bilayer
and protrude outside the lipid bilayers, as shown schematically in Figure 7D (right)
and in the TEM picture (Figure 7D; right bottom).
The k1 rate constant for nuclear formation in the presence of lipid bilayers is
faster than in the absence of lipid bilayers (Table 2) because glucagon monomers
associate with the surface of the lipid bilayer, migrate laterally on the surface of the
lipid bilayer to form oligomeric intermediates, and then subsequently change to
fibril intermediate through a homogeneous nucleation reaction. This two-
dimensional process may be faster than nuclear formation in the three-dimensional
solution state.
The k2 rate constant for fibril elongation in the presence of lipid bilayers is
slower than in the absence of lipid bilayers. As discussed previously, the N-terminal
part of the glucagon molecule in a fibril in the presence of a lipid bilayer remains in
an α-helix which may be stabilized when the helix interacts with the lipid bilayer.
However, after the fibril grows and is released from the lipid bilayer, the N-terminal
α-helix becomes more unstable than the N-terminal β-sheet formed in a fibril that
protrudes from the lipid bilayer. This unstable fibril can grow to the outside of the
lipid bilayer because it potentially acts as a template to form structures identical to
the fibril nuclei formed on the surface of the lipid bilayer. The instability of the
fibril state outside the lipid bilayer results in a decrease in the k2 value for fibril
elongation as compared to the absence of a lipid bilayer.
These results show that glucagon molecules significantly interact with lipid
bilayers during the fibril formation processes. To understand the fibril formation
process under physiological condition, a variety of lipid bilayer systems including a
lipid bilayer in neutral solution were investigated.
6. Fibrillation mechanism of glucagon inside the lipid bilayer in the
neutral condition
Fibril formation processes were investigated for glucagon embedded inside a
lipid bilayer in neutral solutions (i.e., essentially physiological conditions) [42].
Glucagon-induced morphological changes of lipid bilayers and fibril formation
process in a glucagon containing lipid bilayer are shown in Figure 8. The monomers
may aggregate with each other to form oligomers (Figure 8B) likely driven by the
amphipathic nature of the N-terminal and C-terminal α-helices. These oligomers
then change into ellipsoidal fibril intermediates (nuclei) (Figure 8C) through a
homogeneous reaction, as observed by TEM (Figure 8C, bottom). At this stage, the
glucagon intermediates strongly interact with the lipid bilayer to form discoidal
lipid bilayer particles. Subsequently, this ellipsoidal fibril intermediate (nucleus)
interacts with monomeric glucagon inside the lipid bilayer to allow elongation of the
fibril by changing from an α-helix to a β-sheet through a heterogeneous elongation
process (Figure 8D). After a long time standing, fibril networks are formed, and
lipid molecules are compartmentalized (Figure 8E), resulting in increased lipid
molecule mobility and the induction of a gel-like state throughout the sample, now
in an amyloidogenic gel state [53, 54].
The kinetic of fibrillation was thus analyzed using a two-step autocatalytic
mechanism as summarized in Table 2. The k1 rate constant for nuclear formation in
neutral solution is much slower than that in a DMPC bilayer in neutral conditions
(Table 2). In a DMPC/glucagon bilayer, glucagon molecules are condensed inside
the DMPC bilayer, and thus the nucleation rate of glucagon in a DMPC/glucagon
bilayer is much faster than that in neutral solution. The k1 rate constant for nuclear
formation in a lipid bilayer in a neutral solution is slower than in a lipid bilayer in an
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acidic solution. In an acidic solution, glucagon locates on the surface of lipid bilayer
and then migrates laterally on the surface of the lipid bilayer to form oligomers and
subsequently changes to fibril nuclei through homogeneous nucleation reaction. In
contrast, glucagon is deeply embedded inside a lipid bilayer in neutral solution and
thus migrates more slowly inside the lipid bilayer, as reflected in the lower k1 value.
The k2 rate constant for the elongation of glucagon fibrils in a DMPC/glucagon
bilayer is much slower than that in neutral solution. Glucagon molecules in a
DMPC/glucagon bilayer interact strongly with the DMPC bilayer. It therefore takes
a long time to disrupt the interaction with the lipid bilayer and form interaction
with glucagon fibrils. The k2 rate constant for fibril elongation in the presence of
lipid bilayers under neutral condition is significantly slower than that in lipid
bilayers under acidic conditions. Under neutral conditions, glucagon is embedded
deep inside the lipid bilayer, and hence it takes longer to release monomeric gluca-
gon from the lipid bilayer. Therefore, the k2 values for fibril elongation decrease as
compared to the case in a lipid bilayer in acidic conditions.
7. Conclusions
It is demonstrated that glucagon forms fibrils in acidic solution and in the
presence of lipid bilayer (bicelle) in acidic solution. Glucagon aggregates to form
Figure 8.
Schematic diagrams of the morphological states of glucagon-DMPC bilayer systems (DMPC/glucagon; 50/1) at
temperatures above and below the phase transition temperature (Tc = 23°C for DMPC). (A) Glucagon-DMPC
bilayer state 1 day after sample preparation. (B) Glucagon-DMPC bilayer state 2 days after sample
preparation. (C) Glucagon-DMPC bilayer state 4 days after sample preparation with the corresponding TEM
picture shown below. (D) Glucagon-DMPC bilayer state 7 days after sample preparation with the
corresponding TEM picture shown below. (E) Glucagon-DMPC bilayer system 10 days after sample
preparation. The corresponding TEM picture is shown below (ref. [42]).
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fibril intermediates that glow into elongated fibrils. Glucagon intermediates are
formed on the surface of the lipid bilayer in the presence of bicelle. These fibrils are
cytotoxic through their activation of apoptotic processes, similar to β-amyloid and
salmon calcitonin. Kinetic analyses of glucagon fibril formation are performed using
a two-step autocatalytic reaction mechanism comprising fibril nucleation and elon-
gation processes. It is revealed that glucagon forms fibril intermediates and grows
into elongated fibrils inside the lipid bilayer under neutral conditions. These prop-
erties of glucagon fibril formation indicate that the interaction of the glucagon fibril
with lipid bilayers is strongly dependent on the process of fibril formation. A
neutral system is thus considered to reflect the fibril formation process in biological
cells and provides insight into the mechanism underlying cytotoxicity of glucagon
fibrils.
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